Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 4/2012

01-08-2012

Anti-inflammation Effects of Sophora flavescens Nanoparticles

Authors: Chun-Chao Han, Yingzi Wang

Published in: Inflammation | Issue 4/2012

Login to get access

Abstract

The roots of Sophora flavescens was reported to possess many pharmacological activities including anti-inflammatory, antiashmatic, antithelmintic, free radical scavenging and antimicrobial activities. However, the low saturated solubility and dissolution velocity of S. flavescens lead to poor bioavailability. The S. flavescens nanoparticles (SFNP) were prepared by a combination of ultrasound and hydrolysis developed by the authors. The drug dissolution profiles of SFNP in both pH 6.8 and pH 2 media showed complete dissolution within 30 min. The seropharmacology study showed that oral S. flavescens absorption in the SFNP was significantly increased. Anti-inflammation assay revealed the therapeutic efficiency of S. flavescens significantly enhanced upon nanoparticle formation.
Literature
1.
Yagi, A., M. Fukunaga, N. Okuzako, I. Mifuchi, and F. Kawamoto. 1989. Antifungal substances from Sophora flavescens. Shoyakugaku Zasshi 43: 343–347.
2.
Kuroyanagi, M., T. Arakawa, Y. Hirayama, and T. Hayashi. 1999. Antibacterial and antiandrogen flavonoids from Sophora flavescens. Journal of Natural Products 62: 1595–1599.PubMedCrossRef
3.
Kim, D.W., Y.S. Chi, K.H. Son, H.W. Chang, J.S. Kim, S.S. Kang, and H.P. Kim. 2002. Effects of sophoraflavanone G, a prenylated flavonoid from Sophora flavescenes, on cyclooxygenase-2 and in vitro inflammatory response. Archives of Pharmacal Research 25: 329–335.PubMedCrossRef
4.
Hwang, J.S., S.A. Lee, S.S. Hong, K.S. Lee, M.K. Lee, B.Y. Hwang, and J.S. Ro. 2005. Monoamine oxidase inhibitory components from the roots of Sophora flavescens. Archives of Pharmacal Research 28: 190–194.PubMedCrossRef
5.
Jung, H.J., S.S. Kang, S.K. Hyun, and J.S. Choi. 2005. In vitro free radical and ONOO − scavengers from Sophora flavescens. Archives of Pharmacal Research 28: 534–540.PubMedCrossRef
6.
Tang, W., and G. Eisenbrand. 1992. Chinese drugs of plant origin, 931–994. Heidelberg: Springer.CrossRef
7.
Mizoe, T., T. Ozeki, and H. Okada. 2007. Preparation of drug nanoparticle-containing microparticles using a4-fluid nozzle spray drier for oral, pulmonary and injection dosage forms. Journal of Controlled Release 122: 10–15.PubMedCrossRef
8.
Texter, J. 2001. Precipitation and condensation of organic particles. Journal of Dispersion Science and Technology 22: 499–527.CrossRef
9.
Horn, D., and J. Rieger. 2001. Organic nanoparticles in the aqueous phase-theory, experiment and use. Angewandte Chemie (International Ed. in English) 40: 4330–4361.CrossRef
10.
Bilgili, E., R. Hamey, and B. Scarlett. 2004. Production of pigment nanoparticles using a wet stirred media mill with polymeric media. China Part 2:93–100.
11.
Bilgili, E., R. Hamey, and B. Scarlett. 2006. Nano-milling of pigment agglomerates using a wet stirred media mill: Elucidation of the kinetics and breakage mechanisms. Chemical Engineering Science 61: 149–157.CrossRef
12.
Thiruvengadathan, R., Y. Levi-Kalisman, O. Regev, Ultrason. Sonochem. 2007. Synergetic effect of ultrasound and sodium dodecyl sulphate in the formation of CdS nanostructures in aqueous solution 14:398–404.
13.
Entezari, M.H., N. Ghows, and M. Chamsaz. 2005. Combination of ultrasound and discarded tire rubber: removal of Cr (III) from aqueous solution. Journal of Physical Chemistry A 109: 4638–4642.CrossRef
14.
Entezari, M.H., N. Ghows, and M. Chamsaz. 2006. Ultrasound facilitates and improves removal of Cd (II) from aqueous solution by the discarded tire rubber. Journal of Hazardous Materials B 131: 84–89.CrossRef
15.
Mason, T.J. 1990. Sonochemistry: The uses of ultrasound in chemistry, The Royal Society of Chemistry.
16.
Price, G.J. 1992. Current trends in sonochemistry, The Royal Society of Chemistry.
17.
Yu, J.C., J. Yu, W. Ho, and L. Zhang. 2001. Preparation of highly photocatalytic active nano-sized TiO2 particles via ultrasonic irradiation. Chemical Communications 7: 1942–1943.CrossRef
18.
Pérez, J., J. Muñoz-Dorado, T. De-la-Rubia, and J. Martínez. 2002. Biodegradation and biological treatments of cellulose, hemicellulose and lignin: an overview. International Microbiology 5: 53–63.PubMedCrossRef
19.
Moure, A., P. Gullon, H. Domınguez, and J.C. Parajo. 2006. Advances in the manufacture, purification and applications of xylooligosaccharides as food additives and nutraceuticals. Process Biochemistry 41: 1913–1923.CrossRef
20.
Merisko-Liversidge, E., P. Sarpotdar, J. Bruno, S. Hajj, L. Wei, N. Peltier, et al. 1996. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharmaceutical Research 13: 272–278.PubMedCrossRef
21.
Merisko-Liversidge, E., G.G. Liversidge, and E.R. Cooper. 2003. Nanosizing: a formulation approach for poorly-water-soluble compounds. European Journal of Pharmaceutical Sciences 18: 113–120.PubMedCrossRef
22.
VanEerdenbrughB, Froyen.L., Blaton.N. MartensJA, P. Augustijns, M. Brewster, et al. 2007. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. International Journal of Pharmaceutics 338: 198–206.CrossRef
23.
Van Eerdenbrugh, B., L. Froyen, J. Van Humbeeck, J.A. Martens, P. Augustijns, and G. Van den Mooter. 2008. Drying of crystalline drug nanosuspensions—the importance of surface hydrophobicity on dissolution behavior upon redispersion. European Journal of Pharmaceutical Sciences 35: 127–135.PubMedCrossRef
24.
Van Eerdenbrugh, B., L. Froyen, J. Van Humbeeck, J.A. Martens, P. Augustijns, and G. Van Den Mooter. 2008. Alternative matrix formers for nanosuspension solidification: dissolution performance and x-ray microanalysis as an evaluation tool for powder dispersion. European Journal of Pharmaceutical Sciences 35: 344–353.PubMedCrossRef
25.
Jacobs, C., and H. Müller. 2002. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharmaceutical Research 19: 189–194.PubMedCrossRef
26.
Hecq, J., M. Deleers, D. Fanara, H. Vranckx, P. Boulanger, S. Le Lamer, et al. 2006. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. European Journal of Pharmaceutics and Biopharmaceutics 64: 360–368.PubMedCrossRef
27.
Riddick, T. 1968. Control of colloid stability through zeta potential: with a closing chapter on its relationship to cardiovascular disease, Zeta-Meter, Inc.
28.
Grant, D.J.W., and H.G. Brittain. 1995. Solubility of pharmaceutical solids. In: Brittain HG, editor. Physical characterization of pharmaceutical solids, drugs and the pharmaceutical sciences. New York: Marcel Dekker.70: 321–86.
29.
McNeil, S.E. 2005. Nanotechnology for the biologist. Jounal of Leukocyte Biology 78: 585–592.CrossRef
30.
Kesisoglou, F., S. Panmai, and Y. Wu. 2007. Nanosizing-oral formulation development and biopharmaceutical evaluation. Advanced Drug Delivery Reviews 59: 631–644.PubMedCrossRef
31.
Duchêne, D., and G. Ponchel. 1997. Bioadhesion of solid oral dosage forms, why and how? European Journal of Pharmaceutics and Biopharmaceutics 44: 15–23.CrossRef
32.
Vasir, J.K., K. Tambwekar, and S. Garg. 2003. Bioadhesive microspheres as a controlled drug delivery system. International Journal of Pharmaceutics 255: 13–32.PubMedCrossRef
Metadata
Title
Anti-inflammation Effects of Sophora flavescens Nanoparticles
Authors
Chun-Chao Han
Yingzi Wang
Publication date
01-08-2012
Publisher
Springer US
Published in
Inflammation / Issue 4/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-012-9437-6

Other articles of this Issue 4/2012

Inflammation 4/2012 Go to the issue

OriginalPaper

Comparison of Quantiferon Test with Tuberculin Skin Test for the Detection of Tuberculosis Infection in Children

OriginalPaper

Elevated Plasma Platelet Activating Factor, Platelet Activating Factor Acetylhydrolase Levels and Risk of Coronary Heart Disease or Blood Stasis Syndrome of Coronary Heart Disease in Chinese: A Case Control Study

OriginalPaper

Effect of Hochuekkito on Alveolar Macrophage Inflammatory Responses in Hyperglycemic Mice

OriginalPaper

Inhibitory Effects of Ginkgo biloba Extract on Inflammatory Mediator Production by Porphyromonas gingivalis Lipopolysaccharide in Murine Macrophages via Nrf-2 Mediated Heme Oxygenase-1 Signaling Pathways

OriginalPaper

Plasma Melatonin and Urinary 6-Hydroxymelatonin Levels in Patients with Pulmonary Tuberculosis

OriginalPaper

The Functional Interaction Between CDK11p58 and β-1,4-Galactosyltransferase I Involved in Astrocyte Activation Caused by Lipopolysaccharide
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits